PE20120907A1 - Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato - Google Patents

Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato

Info

Publication number
PE20120907A1
PE20120907A1 PE2011001962A PE2011001962A PE20120907A1 PE 20120907 A1 PE20120907 A1 PE 20120907A1 PE 2011001962 A PE2011001962 A PE 2011001962A PE 2011001962 A PE2011001962 A PE 2011001962A PE 20120907 A1 PE20120907 A1 PE 20120907A1
Authority
PE
Peru
Prior art keywords
xrpd
peaks
presenting
methylsulfamate
pirrolo
Prior art date
Application number
PE2011001962A
Other languages
English (en)
Inventor
Ian G Armitage
Reenu Chopra
Martin Ian Cooper
Marianne Langton
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PE20120907A1 publication Critical patent/PE20120907A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UNA SAL DE CLORHIDRATO DE ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHIDRO-1H-INDEN-1-ILAMINO]-7H-PIRROLO[2,3-D]PIRIMIDIN-7-IL}-2-HIDROXICICLOPENTIL)METILSULFAMATO QUE COMPRENDE: (A) UNA FORMA 1 QUE SE CARACTERIZA POR PRESENTAR UN PATRON DE DIFRACCION DE POLVO DE RAYOS X (XRPD) CON PICOS EN ANGULOS 2THETA DE: 9.6º, 13.6º Y 19.1º O 9.6º, 13.6º, 14.5º, 19.1º Y 23.7º; (B) UNA FORMA 2 QUE SE CARACTERIZA POR PRESENTAR UN XRPD CON PICOS EN ANGULOS 2THETA DE: 8.7º, 18.2º Y 23.8º O 8.7º, 18.2º, 19.4º, 23.8º, 24.3º Y 27.5º; (C) UNA FORMA 3A QUE SE CARACTERIZA POR PRESENTAR UN XRPD CON PICOS EN ANGULOS 2THETA DE: 10.9º, 14.6º, 19.5º Y 24.0º O 10.9º, 14.6º, 16.9º, 19.5º, 24.0º Y 25.9º; (D) UNA FORMA 3B QUE SE CARACTERIZA POR PRESENTAR UN XRPD CON PICOS EN ANGULOS 2THETA DE: 10.8º, 16.9º, 23.7º Y 24.0º O 10.8º, 14.5º, 16.9º, 19.3º, 21.2º, 23.7º, 24.0º Y 28.8º; (E) UNA FORMA 3C QUE SE CARACTERIZA POR PRESENTAR UN XRPD CON PICOS EN ANGULOS 2THETA DE: 11.0º, 12.2º Y 24.4º; 11.0º, 12.2º, 14.9º, 19.8º, 24.0º Y 24.4º; (F) UNA FORMA 5 QUE SE CARACTERIZA POR PRESENTAR UN XRPD CON PICOS EN ANGULOS 2THETA DE: 16.7º Y 22.9º O 16.7º, 17.2º, 18.1º Y 22.9º; (G) UNA FORMA 7 QUE SE CARACTERIZA POR PRESENTAR UN XRPD CON PICOS EN ANGULOS 2THETA DE: 15.4º, 17.3º, 19.6º Y 22.5º O 10.0º, 15.4º, 16.6º, 17.3º, 18.0º, 18.3º, 19.6º, 22.0º Y 22.5º. DICHO COMPUESTO ES UN INHIBIDOR DE ENZIMA ACTIVANTE DE E1 UTIL EN EL TRATAMIENTO DEL CANCER
PE2011001962A 2009-05-14 2010-05-13 Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato PE20120907A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21622109P 2009-05-14 2009-05-14

Publications (1)

Publication Number Publication Date
PE20120907A1 true PE20120907A1 (es) 2012-08-18

Family

ID=42396430

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016001604A PE20161222A1 (es) 2009-05-14 2010-05-13 Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato
PE2011001962A PE20120907A1 (es) 2009-05-14 2010-05-13 Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2016001604A PE20161222A1 (es) 2009-05-14 2010-05-13 Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato

Country Status (18)

Country Link
US (2) US9187482B2 (es)
EP (2) EP2430026A1 (es)
JP (3) JP2012526808A (es)
KR (2) KR20120024715A (es)
CN (2) CN104016987A (es)
AU (1) AU2010248151B2 (es)
BR (1) BRPI1012142A2 (es)
CA (1) CA2761256C (es)
IL (1) IL216201A (es)
MX (1) MX2011012108A (es)
NZ (2) NZ621128A (es)
PE (2) PE20161222A1 (es)
PH (1) PH12015501925A1 (es)
RU (1) RU2562245C2 (es)
SG (2) SG10201402148SA (es)
UA (1) UA108986C2 (es)
WO (1) WO2010132110A1 (es)
ZA (1) ZA201108347B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
CN103483342B (zh) 2007-08-02 2016-08-31 米伦纽姆医药公司 合成e1活化酶抑制剂的方法
BRPI1012142A2 (pt) 2009-05-14 2016-03-29 Millennium Pharm Inc sal cloridrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-diidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil) metil sulfamato
US20120115892A1 (en) * 2010-11-05 2012-05-10 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor
MY166889A (en) * 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
US8980850B2 (en) 2011-11-03 2015-03-17 Millennium Pharmaceuticals, Inc. Administration of a NEDD8-activating enzyme inhibitor and hypomethylating agent
SG10201606581RA (en) * 2012-02-17 2016-09-29 Millennium Pharm Inc Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
US9593121B2 (en) 2012-08-03 2017-03-14 Millennium Pharmaceuticals, Inc. Indole substituted pyrrolopyrimidinyl inhibitors of Uba6
CA2886783A1 (en) 2012-10-01 2014-04-10 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
CN105407973A (zh) 2013-05-14 2016-03-16 米伦纽姆医药公司 Nedd8活化酶抑制剂及化学治疗剂的投与
EP3016934B1 (en) 2013-07-02 2018-01-10 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
AU2015284135B2 (en) 2014-07-01 2019-11-28 Takeda Pharmaceutical Company Limited Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
CN106008394B (zh) * 2016-05-23 2018-12-04 中国人民解放军第二军医大学 巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途
JP2020534331A (ja) 2017-09-21 2020-11-26 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． （（１ｓ，２ｓ，４ｒ）−４−｛４−［（１ｓ）−２，３−ジヒドロ−１ｈ−インデン−１−イルアミノ］−７ｈ−ピロロ［２，３−ｄ］ピリミジン−７−イル｝−２−ヒドロキシシクロペンチル）メチルスルファメートの共結晶形態、その製剤及び使用
JP2022521972A (ja) * 2019-02-26 2022-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッド アジュバントとして有用な化合物
KR20210115680A (ko) 2020-03-16 2021-09-27 서희강 연설용 프롬프터
WO2022112951A1 (en) * 2020-11-25 2022-06-02 Takeda Pharmaceutical Company Limited Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622561A (en) 1969-08-18 1971-11-23 Univ Utah Nucleoside sugar esters of sulfamic acid and method for preparation of the same
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
JPS62108897A (ja) 1985-11-05 1987-05-20 Rikagaku Kenkyusho アスカマイシン誘導体及びその合成法並びに制癌剤
GB8813148D0 (en) 1988-06-03 1988-07-06 Glaxo Group Ltd Chemical compounds
GB8826205D0 (en) 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5864033A (en) 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5470898A (en) 1993-06-30 1995-11-28 Montell North America Inc. Sorbitol derivatives as nucleators and clarifiers for polyolefins, and polyolefin compositions obtained therewith
GB9325810D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
GB9325809D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
US6210917B1 (en) 1993-12-29 2001-04-03 The Regents Of The University Of California Method for suppressing multiple drug resistance in cancer cells
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US5973161A (en) 1996-03-18 1999-10-26 The University Of North Carolina At Chapel Hill Enantioselective synthesis of cyclopentenes
US5824657A (en) 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US6734283B1 (en) 1997-12-19 2004-05-11 Millennium Pharmaceuticals, Inc. Human proteins responsible for NEDD8 activation and conjugation
JPH11228446A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
JPH11228422A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
CN1646141B (zh) 2000-10-18 2014-06-25 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
EP2198867A1 (en) 2001-12-07 2010-06-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
WO2003106477A1 (en) 2002-06-01 2003-12-24 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7338957B2 (en) 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
RU2373197C2 (ru) 2004-03-30 2009-11-20 Тайсо Фармасьютикал Ко., Лтд. Пиримидиновые производные, обладающие активностью в отношении мсн
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
PT1848718E (pt) 2005-02-04 2012-10-11 Millennium Pharm Inc Inibidores de enzimas de activação e1
MY171289A (en) * 2006-02-02 2019-10-07 Millennium Pharm Inc Inhibitors of e1 activating enzymes
CN101516850B (zh) 2006-08-08 2014-05-07 米伦纽姆医药公司 适用作e1活化酶抑制剂的杂芳基化合物
CN103483342B (zh) * 2007-08-02 2016-08-31 米伦纽姆医药公司 合成e1活化酶抑制剂的方法
BRPI1012142A2 (pt) 2009-05-14 2016-03-29 Millennium Pharm Inc sal cloridrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-diidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil) metil sulfamato
US8980850B2 (en) 2011-11-03 2015-03-17 Millennium Pharmaceuticals, Inc. Administration of a NEDD8-activating enzyme inhibitor and hypomethylating agent
CN105407973A (zh) 2013-05-14 2016-03-16 米伦纽姆医药公司 Nedd8活化酶抑制剂及化学治疗剂的投与

Also Published As

Publication number Publication date
CA2761256C (en) 2021-01-05
EP3091020B1 (en) 2020-12-30
US20170000792A9 (en) 2017-01-05
BRPI1012142A2 (pt) 2016-03-29
KR20170102381A (ko) 2017-09-08
WO2010132110A1 (en) 2010-11-18
AU2010248151A1 (en) 2011-12-01
US20160030432A1 (en) 2016-02-04
US9187482B2 (en) 2015-11-17
EP3091020A3 (en) 2017-01-11
PE20161222A1 (es) 2016-12-01
SG175929A1 (en) 2011-12-29
PH12015501925A1 (en) 2018-01-22
CN102421780A (zh) 2012-04-18
IL216201A0 (en) 2012-01-31
MX2011012108A (es) 2011-12-08
EP3091020A2 (en) 2016-11-09
JP2017105816A (ja) 2017-06-15
UA108986C2 (uk) 2015-07-10
CA2761256A1 (en) 2010-11-18
JP2012526808A (ja) 2012-11-01
US20110021544A1 (en) 2011-01-27
RU2562245C2 (ru) 2015-09-10
EP2430026A1 (en) 2012-03-21
CN104016987A (zh) 2014-09-03
AU2010248151B2 (en) 2016-07-14
JP2015096547A (ja) 2015-05-21
NZ621128A (en) 2015-08-28
RU2011150826A (ru) 2013-06-20
ZA201108347B (en) 2014-05-26
IL216201A (en) 2015-11-30
SG10201402148SA (en) 2014-07-30
US10016427B2 (en) 2018-07-10
NZ596470A (en) 2014-04-30
KR20120024715A (ko) 2012-03-14

Similar Documents

Publication Publication Date Title
PE20120907A1 (es) Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato
LU92864I2 (fr) Cobicistat ou un de ses sels pharmaceutiquement acceptables
AR122395A2 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
PE20120812A1 (es) Compuestos vinil indazolilo
ES2723277T3 (es) Una forma sólida de clorhidrato de (S)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
CR11741A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
PE20141822A1 (es) Inhibidor de la quinasa reguladora de la senal de apoptosis
PE20121499A1 (es) Formas cristalinas de 3-(2, 6-dicloro-3, 5-dimetoxi-fenil)-1-{6-4[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
CL2009000576A1 (es) Un compuesto {1-etilsulfonil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo o su sal; inhibidor de jak; composicion farmaceutica; y su uso para tratar artritis reumatoide.
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
AR087672A1 (es) Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer
EA201200507A1 (ru) Применение активаторов никотинового ацетилхолинового рецептора альфа 7
EA201290397A1 (ru) 1,3,4-оксадиазол-2-карбоксамидное соединение
PA8850801A1 (es) Compuestos útiles para inhibir chk1
GT201200164A (es) "nuevos compuestos de espiropiperidina"
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
EA201590296A1 (ru) Дейтерированный ибрутиниб
DOP2011000362A (es) Metodo para la preparacion de hidrocloruro de nalmefeno activo
RS52255B (en) NALMEFEN HYDROCHLORIDE DIHYDRATE
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
FR2936175B1 (fr) Machine et procede d'usinage d'une piece par micro-electroerosion
PE20080338A1 (es) 4-[5-(2-amino-etansulfonil)-isoquinolin-7-il]-fenol como inhibidor de akt (proteina cinasa)
IN2012DN00765A (es)
DOP2013000249A (es) Monohidrato de derivados de aza-adamantano
GT200700074A (es) Fungicidas

Legal Events

Date Code Title Description
FC Refusal
FD Application declared void or lapsed